Avidity Biosciences (RNA)
(Real Time Quote from BATS)
$47.87 USD
-0.64 (-1.32%)
Updated Oct 2, 2024 09:52 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Avidity Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 595 | 611 | 406 | 328 | 95 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 16 | 12 | 6 | 4 | 1 |
Total Current Assets | 611 | 623 | 411 | 332 | 96 |
Net Property & Equipment | 8 | 6 | 5 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 629 | 639 | 428 | 334 | 97 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 34 | 33 | 14 | 8 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 11 | 9 | 3 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 28 | 5 | 5 | 4 | 4 |
Total Current Liabilities | 81 | 52 | 30 | 15 | 10 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 41 | 1 | 7 | 12 | 15 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 2 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 128 | 61 | 46 | 28 | 28 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 135 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,071 | 939 | 566 | 373 | -43 |
Retained Earnings | -571 | -359 | -185 | -67 | -22 |
Other Equity | 0 | -3 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 501 | 578 | 381 | 306 | 69 |
Total Liabilities & Shareholder's Equity | 629 | 639 | 428 | 334 | 97 |
Total Common Equity | 501 | 578 | 381 | 306 | -65 |
Shares Outstanding | 74.10 | 69.70 | 46.90 | 37.50 | NA |
Book Value Per Share | 6.76 | 8.29 | 8.13 | 8.17 | 0.00 |
Fiscal Year End for Avidity Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,299 | 916 | 595 | 543 | 577 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 30 | 19 | 16 | 13 | 18 |
Total Current Assets | 1,329 | 934 | 611 | 555 | 595 |
Net Property & Equipment | 9 | 9 | 8 | 8 | 8 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 1 | 1 | 1 | 1 |
Total Assets | 1,347 | 951 | 629 | 573 | 611 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 41 | 37 | 34 | 32 | 32 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 8 | 14 | 11 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 27 | 26 | 28 | 2 | 4 |
Total Current Liabilities | 84 | 75 | 81 | 49 | 45 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 38 | 40 | 41 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 126 | 121 | 128 | 56 | 52 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,932 | 1,471 | 1,071 | 1,030 | 1,020 |
Retained Earnings | -710 | -640 | -571 | -510 | -458 |
Other Equity | 0 | 0 | 0 | -2 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,221 | 831 | 501 | 517 | 559 |
Total Liabilities & Shareholder's Equity | 1,347 | 951 | 629 | 573 | 611 |
Total Common Equity | 1,221 | 831 | 501 | 517 | 559 |
Shares Outstanding | 109.80 | 95.60 | 74.10 | 74.10 | 74.10 |
Book Value Per Share | 11.12 | 8.69 | 6.76 | 6.98 | 7.55 |